01363nam a2200205   4500001000700000010001800007090001100025100004100036101000800077200013700085210008300222215001700305330056300322606002700885606003200912606001700944710006800961955001101029995011701040387625  a9789291683154  a387625  a20090420d2008       y0pory50      ba  aeng  aTowards a better understanding of drug-related public expenditure in EuropefEuropean Monitoring Centre for Drugs and Drug Addiction  aLuxembourgcOffice for Official Publications of the European Communitiesd2008  a28 p.d30 cm  aIntroductory note and acknowledgements. Introduction. Drug-related economic evaluation: key issues. Efficiency. Addressing efficiency through economic evaluation. Perspectives in economic evaluation. Cost studies. A particular perspective on costing: public expenditure. Drug-related public expenditure in Europe. Labelled expenditure. Non-labelled expenditure. Total drug-related expenditure in Europe. Conclusions and recommendations. Limitations of the study and future developments. The flip side of drug-related public expenditure. References. Glossary.  aESTUPEFACIENTE9343050  aDESPESAS PÚBLICAS9246095  aOEDT9321506  aEUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION9351987  xOferta  104PJ_20_000000000000000_B_452022-06-066PJ299229418625aPJcPJfPJ129922kPJ20.B.4n2022-06-06o0rMOxOferta